The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on uveal melanoma rabbit model

Current Eye Research

Volumn 24, Issue 2, 2002, Pages 86-91

  Ozerdem, Ugur ^a   Mach Hofacre, Beata ^a   Varki, Nissi ^a   Folberg, Robert ^a   Mueller, Arthur J ^a   Ochabski, Renata ^a   Pham, Tony ^a   Appelt, Krzysztof ^a   Freeman, William R ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Metalloproteinase; Prinomastat; Retinal detachment; Trauma

Indexed keywords

CYCLOSPORIN A; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; MATRIX METALLOPROTEINASE; ORGANIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CONTROLLED STUDY; DRUG EFFECT; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; RABBIT; TUMOR XENOGRAFT; UVEA MELANOMA; ANIMAL; CANCER TRANSPLANTATION; DRUG ANTAGONISM; EXPERIMENTAL MELANOMA; EYE FUNDUS; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; UVEA TUMOR; XENOGRAFT;

ANIMAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; ENZYME INHIBITORS; FUNDUS OCULI; HUMAN; MATRIX METALLOPROTEINASES; MELANOMA, EXPERIMENTAL; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; RABBITS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRANSPLANTATION, HETEROLOGOUS; UVEAL NEOPLASMS; ANIMALS; HUMANS; ORGANIC CHEMICALS;

EID: 0035986464     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1076/ceyr.24.2.86.8159     Document Type: Article

References (28)

1. Expression of integrins, degradative enzymes and their inhibitors in uveal melanoma: Differences between in vitro and in vivo expression
2. Expression of integrin alpha5beta1 and MMPs associated with epithelioid morphology and malignancy of uveal melanoma
3. Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit
4. Human T lymphocytes express a member of the Matrix Metalloproteinase gene family
5. Expression of matrix metalloproteinases by human plasma cells and B lymphocytes
6. Preclinical and clinical studies of MMP inhibitors in cancer
7. MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma
8. A comparison of ocular melanocyte and uveal melanoma cell invasion and the implication of alpha1beta1, alpha4beta1 and alpha6beta1 integrins
9. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
10. Establishment of pigmented choroidal melanomas in a rabbit model
11. Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes
12. Heterotransplantation of human uveal melanoma
13. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor
14. Relative importance of quantifying area and vascular patterns in uveal melanomas
15. Evaluation of the human choroidal melanoma rabbit model for studying microcirculation patterns with confocal ICG and histology
16. A new matrix metalloproteinase inhibitor SI-27 induces apoptosis in several human myeloid leukemia cell lines and enhances sensitivity to TNF alpha-induced apoptosis
17. A simple noncontact wide-angle fundus photography procedure for clinical and research use
18. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy
19. The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy
20. Evaluation of long-term effects of intraocular injections of AG3340, a selective matrix metalloprotease inhibitor
21. The induction of 72-kD gelatinase in T cells upon adhesion to endothelial cells is VCAM-1 dependent
22. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
23. Current approaches to the diagnosis and management of choroidal melanomas
24. Human B lymphocytes synthesize the 92-kDa gelatinase, matrix metalloproteinase-9
25. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein: A new prognostic marker in uveal melanoma?
26. Human T lymphocytes synthesize the 92 kDa type IV collagenase (gelatinase B)
27. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesisin vivo
28. Induction of metalloproteinase activity in human T-lymphocytes